Enterprise Financial Services Corp (EFSC)’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
– Sell
-21
Closed -$2K – 839
2021
Q2
$2K Hold
21
– – ﹤0.01% 1142
2021
Q1
$2K Hold
21
– – ﹤0.01% 1151
2020
Q4
$1K Hold
21
– – ﹤0.01% 1215
2020
Q3
$1K Hold
21
– – ﹤0.01% 1190
2020
Q2
$1K Buy
21
+3
+17% +$190 ﹤0.01% 1198
2020
Q1
$1K Buy
+18
New +$1.02K ﹤0.01% 1172
2016
Q4
– Sell
-87
Closed -$6K – 1078
2016
Q3
$6K Hold
87
– – ﹤0.01% 699
2016
Q2
$6K Hold
87
– – ﹤0.01% 673
2016
Q1
$6K Buy
+87
New +$5.29K ﹤0.01% 669

Other funds holding LGND

Enterprise Financial Services Corp (EFSC)'s LGND Position: Q3 2021 in Review

Enterprise Financial Services Corp (EFSC) sold out of Ligand Pharmaceuticals (LGND) in Q3 2021, closing a stake of 21 shares — an estimated $2K sold.

Enterprise Financial Services Corp (EFSC) first reported a position in LGND in Q1 2016 and held it in 9 quarters. The position peaked at $6K in Q3 2016. 207 funds tracked by Wall St. Rank hold LGND as of Q3 2021.

  • Enterprise Financial Services Corp (EFSC) reported no remaining Ligand Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Enterprise Financial Services Corp (EFSC) sold 21 Ligand Pharmaceuticals shares in Q3 2021, an estimated $2K.
  • Enterprise Financial Services Corp (EFSC) first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 9 quarters.
  • Enterprise Financial Services Corp (EFSC)'s Ligand Pharmaceuticals position peaked at $6K in Q3 2016.
  • 207 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2021.

Based on Enterprise Financial Services Corp (EFSC)'s 13F filing for Q3 2021, filed 15 Nov 2021.